Supportive-expressive group therapy for women with metastatic breast cancer: Survival and psychosocial outcome from a randomized controlled trial

David W Kissane, Brenda Grabsch, David Murray Clarke, Graeme Crawford Smith, Anthony W Love, Sidney Bloch, Raymond Snyder, Yuelin Li

Research output: Contribution to journalArticleResearchpeer-review

230 Citations (Scopus)

Abstract

BACKGROUND: Mixed reports exist about the impact of supportive-expressive group therapy (SEGT) on survival. METHODS: From 485 women with advanced breast cancer recruited between 1996-2002, 227 (47 ) consented and were randomized within an average 10 months of cancer recurrence in a 2:1 ratio to intervention with 1 year or more of weekly SEGT plus three classes of relaxation therapy (147 women) or to control receiving three classes of relaxation therapy (80 women). The primary outcome was survival; psychosocial well-being was appraised secondarily. Analysis was by intention-to-treat. RESULTS: SEGT did not prolong survival (median survival 24.0 months in SEGT and 18.3 in controls; univariate hazard ratio for death 0.92 [95 CI, 0.69-1.26]; multivariate hazard ratio, 1.06 [95 CI, 0.74-1.51]). Significant predictors of survival were treatment with chemotherapy and hormone therapy (p
Original languageEnglish
Pages (from-to)277 - 286
Number of pages10
JournalPsycho-Oncology
Volume16
Issue number4
Publication statusPublished - 2007

Cite this

@article{5ded5a8ac3f441a5bc355e380a55dead,
title = "Supportive-expressive group therapy for women with metastatic breast cancer: Survival and psychosocial outcome from a randomized controlled trial",
abstract = "BACKGROUND: Mixed reports exist about the impact of supportive-expressive group therapy (SEGT) on survival. METHODS: From 485 women with advanced breast cancer recruited between 1996-2002, 227 (47 ) consented and were randomized within an average 10 months of cancer recurrence in a 2:1 ratio to intervention with 1 year or more of weekly SEGT plus three classes of relaxation therapy (147 women) or to control receiving three classes of relaxation therapy (80 women). The primary outcome was survival; psychosocial well-being was appraised secondarily. Analysis was by intention-to-treat. RESULTS: SEGT did not prolong survival (median survival 24.0 months in SEGT and 18.3 in controls; univariate hazard ratio for death 0.92 [95 CI, 0.69-1.26]; multivariate hazard ratio, 1.06 [95 CI, 0.74-1.51]). Significant predictors of survival were treatment with chemotherapy and hormone therapy (p",
author = "Kissane, {David W} and Brenda Grabsch and Clarke, {David Murray} and Smith, {Graeme Crawford} and Love, {Anthony W} and Sidney Bloch and Raymond Snyder and Yuelin Li",
year = "2007",
language = "English",
volume = "16",
pages = "277 -- 286",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley & Sons",
number = "4",

}

Supportive-expressive group therapy for women with metastatic breast cancer: Survival and psychosocial outcome from a randomized controlled trial. / Kissane, David W; Grabsch, Brenda; Clarke, David Murray; Smith, Graeme Crawford; Love, Anthony W; Bloch, Sidney; Snyder, Raymond; Li, Yuelin.

In: Psycho-Oncology, Vol. 16, No. 4, 2007, p. 277 - 286.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Supportive-expressive group therapy for women with metastatic breast cancer: Survival and psychosocial outcome from a randomized controlled trial

AU - Kissane, David W

AU - Grabsch, Brenda

AU - Clarke, David Murray

AU - Smith, Graeme Crawford

AU - Love, Anthony W

AU - Bloch, Sidney

AU - Snyder, Raymond

AU - Li, Yuelin

PY - 2007

Y1 - 2007

N2 - BACKGROUND: Mixed reports exist about the impact of supportive-expressive group therapy (SEGT) on survival. METHODS: From 485 women with advanced breast cancer recruited between 1996-2002, 227 (47 ) consented and were randomized within an average 10 months of cancer recurrence in a 2:1 ratio to intervention with 1 year or more of weekly SEGT plus three classes of relaxation therapy (147 women) or to control receiving three classes of relaxation therapy (80 women). The primary outcome was survival; psychosocial well-being was appraised secondarily. Analysis was by intention-to-treat. RESULTS: SEGT did not prolong survival (median survival 24.0 months in SEGT and 18.3 in controls; univariate hazard ratio for death 0.92 [95 CI, 0.69-1.26]; multivariate hazard ratio, 1.06 [95 CI, 0.74-1.51]). Significant predictors of survival were treatment with chemotherapy and hormone therapy (p

AB - BACKGROUND: Mixed reports exist about the impact of supportive-expressive group therapy (SEGT) on survival. METHODS: From 485 women with advanced breast cancer recruited between 1996-2002, 227 (47 ) consented and were randomized within an average 10 months of cancer recurrence in a 2:1 ratio to intervention with 1 year or more of weekly SEGT plus three classes of relaxation therapy (147 women) or to control receiving three classes of relaxation therapy (80 women). The primary outcome was survival; psychosocial well-being was appraised secondarily. Analysis was by intention-to-treat. RESULTS: SEGT did not prolong survival (median survival 24.0 months in SEGT and 18.3 in controls; univariate hazard ratio for death 0.92 [95 CI, 0.69-1.26]; multivariate hazard ratio, 1.06 [95 CI, 0.74-1.51]). Significant predictors of survival were treatment with chemotherapy and hormone therapy (p

UR - http://onlinelibrary.wiley.com.ezproxy.lib.monash.edu.au/doi/10.1002/pon.1185/abstract

M3 - Article

VL - 16

SP - 277

EP - 286

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 4

ER -